Drugs / VIR-1111
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04725877 | Dec 2020 → Dec 2022 | HIV infectious disease | Vir Biotechnology, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIR-1111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04725877 ↗ |
| Modality | Vaccine | “Prototype Human CMV-based Vaccine” NCT04725877 ↗ |
| Route | Subcutaneous | “1 mL subcutaneous injection” NCT04725877 ↗ |